AxoGen Q2 revenue beats estimates on breast procedure growth
AxoGen Q2 revenue beats estimates on breast procedure growth
Overview
Peripheral nerve repair firm's Q2 revenue rose 23% yr/yr, beating analyst expectations
Adjusted EPS for Q2 met analyst expectations
Company cites broad-based growth across target markets, led by breast procedures
Outlook
AxoGen expects 2026 revenue of at least $279 mln, up at least 24%
Company sees 2026 gross margin at least 73%
AxoGen anticipates positive free cash flow for full-year 2026
Result Drivers
BREAST PROCEDURE GROWTH - Co said accelerating year-over-year growth in breast procedures, exceeding 50%, was a key driver of revenue and impacted product mix
BROAD-BASED MARKET GAINS - Co cited strong growth across Extremities, Oral Maxillofacial & Head and Neck, and Breast segments, supported by over 20% year-over-year account productivity
SALES FORCE AND INSURANCE COVERAGE - Co attributed results to expanded sales force coverage and improved commercial insurance coverage and payment
Company press release: ID:nGNX7ylJ2K
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $69.70 mln | $67.10 mln (9 Analysts) |
Q2 Adjusted EPS | Meet | $0.12 | $0.12 (7 Analysts) |
Q2 Adjusted Net Income |
| $7.30 mln |
|
Q2 Net Loss |
| $1.50 mln |
|
Q2 Adjusted EBITDA |
| $8.40 mln |
|
Q2 Gross Margin |
| 72.70% |
|
Reuters Recommended Reads
July 29 - Integra LifeSciences Q2 revenue slightly beats, adjusted EPS tops estimates
July 28 - UK's Creo Medical H1 revenue rises 45%
July 27 - Universal Health Services cuts 2026 forecast on Medicaid reimbursement uncertainty
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)